## REGN: Regeneron Pharmaceuticals, Inc. - XLV: Healthcare

### Executive Summary

VALUE thesis: PEG 1.46 indicates fundamental undervaluation. Quality metrics strong (ROE 15%). Consistent execution (3/4 quarters beat estimates).

- **Horizon:** 20-60 days (position)
- **Risk Profile:** Lower - fundamental undervaluation
- **Stop Type:** Fixed 2xATR ($708.13)
- **If Wrong:** Exit if fundamentals deteriorate or stop hit
- **Invalidation:** PEG > 1.5 or earnings miss

### News

- **Articles:** 10
- **Sentiment:** Bullish (Bullish: 6, Bearish: 0)

**1. Woodstock Corp Acquires 8,589 Shares of Regeneron Pharmaceuticals, Inc. $REGN**
- Source: MarketBeat | 20251217T143458 | Bullish | Relevance: 100%
- Woodstock Corp significantly increased its stake in Regeneron Pharmaceuticals (NASDAQ:REGN) by 107.1% during the third quarter, purchasing an additional 8,589 shares to own 16,610 shares valued at $9.34 million. This move comes amidst mixed insider activity, with significant sales by a director and a VP, while institutional ownership remains high at 83.31%. Analysts have a "Moderate Buy" rating on REGN with an average price target of $779.45.

**2. Sicart Associates LLC Makes New $3.93 Million Investment in Regeneron Pharmaceuticals, Inc. $REGN**
- Source: MarketBeat | 20251217T123820 | Somewhat-Bearish | Relevance: 100%
- Sicart Associates LLC has made a new investment of $3.93 million in Regeneron Pharmaceuticals (NASDAQ:REGN) during the third quarter of 2025, acquiring 6,981 shares. This comes as Regeneron outperformed quarterly estimates, and analysts have issued a "Moderate Buy" consensus with an average price target of $779.45. Despite some insider selling, institutional investors now own 83.31% of the company's stock.

**3. Leerink Partners raises Regeneron stock price target to $873 on growth outlook**
- Source: Investing.com | 20251217T100843 | Bullish | Relevance: 100%
- Leerink Partners has increased its price target for Regeneron Pharmaceuticals (NASDAQ:REGN) to $873 from $710, maintaining an Outperform rating due to strong growth prospects. This revised outlook is driven by anticipated 11% five-year compound annual growth in EPS, primarily fueled by EYLEA HD's projected success and positive updates on Dupixent. The new target is based on an 18.0x multiple applied to Leerinkâ€™s 2027 diluted EPS estimate, reflecting differentiated growth compared to industry peers.

**4. Regeneron Pharmaceuticals, Inc. $REGN Shares Purchased by Assenagon Asset Management S.A.**
- Source: MarketBeat | 20251217T090841 | Bullish | Relevance: 100%
- Assenagon Asset Management S.A. increased its stake in Regeneron Pharmaceuticals (NASDAQ:REGN) by 12.9% in the third quarter, now owning 477,810 shares valued at approximately $268.66 million. Regeneron Pharmaceuticals reported strong quarterly earnings, beating analyst estimates with EPS of $11.83 and revenue of $3.75 billion, and maintains a "Moderate Buy" consensus rating among analysts. Insider transactions show recent sales by a director and a VP, while institutional investors collectively hold 83.31% of the company's stock.

**5. Is Regeneron Still Attractively Priced After Its Recent Share Price Surge?**
- Source: Simply Wall Street | 20251217T023440 | Bullish | Relevance: 100%
- Regeneron Pharmaceuticals has seen a recent share price surge but a Discounted Cash Flow (DCF) analysis suggests the stock is undervalued by 53.1%. Additionally, its Price to Earnings (PE) ratio of 16.73x is below both the biotech industry average and its proprietary Fair Ratio, further indicating undervaluation based on company-specific fundamentals. The article encourages investors to use "Narratives" on Simply Wall St to align their views with financial data for a more personalized valuation.

### Analyst Activity

**Target Signal:** BULLISH (Raises: 6, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-12 | Morgan Stanley | $768 | $767 | +0% |
| 2025-12-10 | Wells Fargo | $745 | $700 | +6% |
| 2025-12-04 | Canaccord Genui | $1057 | $850 | +24% |
| 2025-12-04 | BMO Capital | $850 | $725 | +17% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-12 | Morgan Stanley | main | Equal-Weight |
| 2025-12-10 | Wells Fargo | main | Equal-Weight |
| 2025-12-04 | Canaccord Genui | main | Buy |
| 2025-12-04 | BMO Capital | main | Outperform |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_BUYING** |
| Buys | 9 ($97.67M) |
| Sells | 15 ($32.83M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 44.7% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 6 / 4 |

**Top Holders:**
- Vanguard Group Inc: 8.8% (-4.0%)
- Blackrock Inc.: 8.6% (-4.7%)
- JPMORGAN CHASE & CO: 7.9% (+106.7%)
- State Street Corpora: 4.5% (-2.9%)
- Dodge & Cox Inc.: 4.4% (+18.9%)

### Key Risks

1. Heavy insider selling: $33M sold (15 transactions in 90 days).
2. Market regime shift could impact momentum names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- Analyst target momentum: 6 raises (avg +13%) could attract flows.
- AI/machine learning initiatives could drive multiple expansion if executed.

### Fundamentals

PEG ratio 1.46 suggests fair value with growth premium. Quality metrics strong (margin 32%). Balance sheet: strong liquidity (4.1x), low leverage (D/E 0.30), $1.4B free cash flow. Analyst sentiment positive (6 raises, avg +13%). Insider buying signal ($97.7M), management confidence. Institutional flow bullish (6 buying vs 4 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $79.4B |
| Beta | 0.37 |
| 52W Range | $476.49 - $790.98 |
| Short Interest | 3.2% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 1.46 |
| Forward P/E | 19.5 |
| Current P/E | 17.3 |
| YoY Growth | -11.2% |
| EPS Direction | RISING |

### Technicals

MRS_20 improving modestly (+0.9% over 5 days). Below STRENGTH zone by 2.6pp (needs >4.0% for momentum thesis). MRS_5 at 0.1% confirms short-term momentum alignment. Full SMA alignment bullish (above 20/50/200 SMAs). MACD histogram bearish (-2.74), momentum weakening. RSI neutral at 60. OFD pattern: +DBN (Indecision).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | 1.37% (CS: 54) | Neutral |
| RSI_14 | 59.6 | Neutral |
| MACD Histogram | -2.74 | Bearish |
| vs SMA20 | 1.007x | Above |
| vs SMA50 | 1.111x | Above |
| vs SMA200 | 1.247x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** VALUE

### Trade Setup

- **Entry:** $748.71
- **Stop Loss:** $708.13 (5.4% risk)
- **Target:** $829.87 (R:R method)
- **Risk/Reward:** 2.00:1
- **Target Reasoning:** VALUE thesis targets 2.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 23
- **Position Value:** $17,220.33
- **Portfolio %:** 17.22%
- **Risk Dollars:** $950.00
- **Risk Per Trade:** 0.95%
- **Modifiers:** L1 95% | L2 100% | Combined 0.95x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 0.95x |
| L2 Sector | NEUTRAL (Zone E) | 1.00x |

*NORMAL regime with cautious positioning ahead of CPI data. VIX at moderate 16.87 with positive yield curve suggesting stable growth, but narrow breadth at 51.8% indicates selective participation. Banking sector optimism and corporate resilience provide support, though AI volatility creates pockets of uncertainty.*

### Earnings

**Next:** 2026-02-03 (Est: $10.77)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $9.64 | $11.83 | +22.7% |
| 2025Q2 | $8.44 | $12.89 | +52.7% |
| 2025Q1 | $8.48 | $8.22 | -3.0% |
| 2024Q4 | $11.19 | $12.07 | +7.8% |

---
*RULE-based L3 | 2026-01-06 16:38 | MRS_20*